BIO CEO Advisory Committee

  • Recommend
  • Tweet
  • Print
  • Email


Andrew Dickinson
Managing Director, Head of Life Sciences, Lazard

Andrew Dickinson joined Lazard's Healthcare Group in 2007 and is a Managing Director based in San Francisco. Mr. Dickinson has advised on transactions including the acquisition of ViroPharma for Shire, the acquisition of Onyx for Amgen, the acquisition of Human Genome Sciences for GSK, the sale of Anadys to Roche, the sale of Abraxis BioScience to Celgene, the sale of Oriel to Novartis/Sandoz, the acquisition of Noven for Hisamitsu, the sale of APP to Fresenius and the sale of Aspreva to Galenica. Prior to joining Lazard, Mr. Dickinson served as a Senior Legal Advisor to Gilead Sciences and as General Counsel and Vice President of Corporate Development at Myogen, Inc. While at Myogen, Mr. Dickinson managed the strategic process that culminated in Gilead's acquisition of Myogen (2006) and led complex licensing and partnership transactions, including a research and development collaboration with Novartis and a commercial development collaboration with GlaxoSmithKline. Prior to joining Myogen, Mr. Dickinson worked at Cooley Godward LLP and Kirkland & Ellis, LLP where he advised on public and private merger and acquisition transactions as well as debt and equity offerings, private equity fund formations and venture capital financings. University of Colorado, B.A. in Molecular, Cellular and Developmental Biology, Loyola University of Chicago, J.D. (cum laude)

Bruce Booth
Partner, Atlas Ventures

Bruce Booth is a partner in the life sciences group and focuses on novel biopharmaceutical products and therapeutic platforms with the potential for breakthrough medical impact. 

Bruce has been instrumental in the creation, founding and launch of a number of new biotech startups, with an emphasis on innovative capital efficient approaches for drug discovery.  He is currently chairman of miRagen, Rodin, Padlock, and Quartet, and also serves on the boards of Nimbus, Zafgen, Bicycle, LTI, and Unum. For several of these companies, he led their incubation at Atlas as acting CEO during their formative stages. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), Proprius (acquired by Cypress Biosciences), and a number of other ventures.

Prior to joining Atlas in 2005, Bruce was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, where he helped to build the Pharma R&D practice.

Bruce serves on UCB Pharma’s Scientific Advisory Board, Shire’s Scientific Advisory Board, and Pfizer’s Healthcare “R&D 2020″ Innovation Think Tank, as well as several other advisory boards for academic medical centers.  He also joined Science Exchange’s Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research.

Bruce blogs about life science venture capital topics at, which is also syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology.  In 2010, Bruce was named to Boston Business Journal’s “40 under 40” list.

John Chambers
Vice-Chairman and Head of Healthcare Investment Banking

John Chambers is the Vice-Chairman and Head of Healthcare Investment Banking group at ROTH Capital Partners. Mr. Chambers joined ROTH in December 2009. Mr. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, he was co-head of investment banking at Rodman & Renshaw. Chambers has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. He has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors.

Chambers earned his M.B.A. from Columbia Business School and his B.S. in mechanical engineering from Union College. He is based in Roth Capital’s New York office.

Stephen Chang
Vice President Research and Development, New York Stem Cell Foundation

As the Vice President for Research and Development at The New York Stem Cell Foundation, Dr. Stephen Chang has overall responsibility for planning, coordinating, and managing the activities of the research department. In this role, he provides senior leadership in the areas of research and development, oversight of short and long term projects with regulations and policies related to administration and  business units, partnerships with industry and other research institutions, and monitoration and evaluation of projects.

Prior to joining NYSCF, Dr. Chang served as Chief Scientific Officer of Stemgent upon the company's founding in 2008. He was previously the CEO of Multicell Technologies and continues as a director of this company.

Dr. Chang is president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative lifesaving medications. He is also a board member of Histogen, Inc., a privately held company in regenerative medicine.

Dr. Chang received his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine. Areas of research interest include translational applications of basic science to pharmaceutical products.

Gerald Commissiong 
CEO, Amarantus

Mr. Commissiong is President, CEO and a member of the Board of Directors of Amarantus, the company he co-founded with John Commissiong, PhD in 2008. From the inception of the Company, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer where his duties included strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business and corporate development. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.

Mike King
Managing Director or Research, JMP Securities

Mike King is a Managing Director and senior research analyst covering the biotechnology industry.

Prior to joining JMP, Mike was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, Mike served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mike has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co.

In 2013, Mike ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal.

Mike holds a BA in finance from The Bernard M. Baruch College of the City University of New York.


Oleg Nodelman
Founder & Managing Director, EcoR1 Capital

Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based, value-oriented healthcare investment fund.  EcoR1 capitalizes on opportunities in the biotechnology sector and mitigates risk through a highly engaged investment process, emphasizing the value of identifying and recruiting premier human capital in all aspects of corporate management and scientific leadership. 

Prior to EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners L.P., one of the oldest dedicated biotechnology hedge funds.  At BVF, Mr. Nodelman’s responsibilities included all aspects of the business including opportunity generation, deep diligence, portfolio management and trading.  Prior to joining BVF in 2001, Mr. Nodelman was a consultant with Mercer Management Consulting (now Oliver Wyman), a consulting firm focused on strategy, operations, risk management, organizational transformation and leadership development.  At Mercer, he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. 

Mr. Nodelman is on the Board of Addex Therapeutics (SIX: ADXN) and a is member of the President's Council at the Gladstone Institute. He holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.

Julie Papanek
Principal, Canaan Partners

Julie joined Canaan Partners, a technology and healthcare venture capital fund with $4.2 billion under management, in 2013. As a Principal, she concentrates on biopharmaceutical, digital health and consumer medical device investments.  Prior to joining Canaan Partners, Julie worked at Genentech in a variety of roles spanning business development, development and commercial primarily within oncology and endocrinology.  She currently observes the boards of Cellular Research, Dermira, Aldea Pharmaceuticals, Chrono Therapeutics and CytomX Therapeutics.

Julie earned her MBA from Stanford¹s Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.

Dennis J. Purcell
Founder and Senior Advisor, Aisling Capital

Mr. Purcell is the Founder and Senior Advisor to Aisling Capital.  Since February 2000, he served as the Senior Managing Partner of the Partnership.

The Partnership has approximately $1.7 billion of assets under management and has invested in over seventy-five companies across three funds since its inception.

Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) and was a member of the Operating Committee.  While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities.  Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. 

Mr. Purcell currently has served on the Board of Directors of numerous public and private companies.  He is also a member of the Board of the Life Sciences Foundation, L.E.K. consulting, a Special Advisor to Poliwogg Holdings, Inc. and an external Advisory Board Member of the NYU Office of Therapeutics Alliances. He has previously served on the Boards of the Biotechnology Industry Organization, the New York Biotechnology Association, the Irvington Institute, and was a member of the Advisory Council of Harvard Medical School.

Mark Schoenebaum
Senior Managing Director, ISI Strategy and Investment

Mark Schoenebaum is a Senior Managing Director, Head of ISI’s Health Care Research Team, and is ISI’s Biotechnology & Pharmaceuticals/Major Analyst. Prior to joining ISI, Dr. Schoenebaum was a Managing Director and Senior Biotechnology Analyst at Deutsche Bank. Prior to that, Dr. Schoenebaum held a similar position at Bear Stearns. He has been ranked Institutional Investor #1 Biotechnology analyst for the past 10 consecutive years and has been the #1 Pharmaceuticals analyst for 2 straight years (Mark first initiated on the Pharmaceuticals space 3 years ago). In 2013, Dr. Schoenebaum was inducted into Institutional Investor’s All-America Research Team Hall of Fame, an award given to analysts who have earned at least ten #1 rankings.

Dr. Schoenebaum graduated from Indiana University with highest distinction in 1996 with a BA and received an MD from the Johns Hopkins University School of Medicine in 2000.

Nathan Tinker

Nathan has been Executive Director of NewYorkBIO since 2007. As Executive Director, Nathan serves as a spokesman and advocate for the state’s industry.  He comes to the Association with a deep knowledge and awareness of the industry and its unique strengths in New York an he has more than 20 years of experience in working with both global and emerging technology companies.  Immediately prior to joining NYBA, Dr. Tinker served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group.  Before that, Nathan was Co-Founder and Executive Vice President of the NanoBusiness Alliance, the national trade association for nanotechnology.  Dr. Tinker began his career in market research and communications, serving such clients as Apple, eSpeed, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo!, CSX, and many others.

Dr. Tinker lends his talent and knowledge to industry on corporate boards, including the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and Namar Consulting, as well as with non-profit groups, including Nanotechnology Commercialization Association and the Kingsborough College Bioscience Advisory Committee.